Prof Solange Peters presents data during a press conference at the 2019 ESMO congress from the CheckMate-227 trial.
This was a trial looking at the two immunotherapy drug combination of nivolumab plus ipilimumab as treatment for a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy.
Watch Dr Marina Garassino's comment here.
Watch Dr Marina Garassino's interview with ecancer here.
Read more about the study here.